FELIX
CARBONELL RAMON

EMÉRITO/A UNIVERSIDAD

Foto de FELIX

Foto de Hospital Universitario Puerta de Hierro

Hospital Universitario Puerta de Hierro

Madrid, España

Publicacions en col·laboració amb investigadors/es de Hospital Universitario Puerta de Hierro (4)

2019

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
Haematologica, Vol. 104, Núm. 11, pp. 2249-2257

2014

Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)
Leukemia and Lymphoma, Vol. 55, Núm. 5, pp. 1007-1012
Vascular Endothelial Growth Factor a ( VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia
PLoS ONE, Vol. 9, Núm. 6

2013

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
Blood, Vol. 122, Núm. 24, pp. 3951-3959